These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 25773405)
1. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Buckingham B; Cheng P; Beck RW; Kollman C; Ruedy KJ; Weinzimer SA; Slover R; Bremer AA; Fuqua J; Tamborlane W; Diabetologia; 2015 Jun; 58(6):1167-74. PubMed ID: 25773405 [TBL] [Abstract][Full Text] [Related]
2. The Association Between HbA Seyed Ahmadi S; Westman K; Pivodic A; Ólafsdóttir AF; Dahlqvist S; Hirsch IB; Hellman J; Ekelund M; Heise T; Polonsky W; Wijkman M; Schwarcz E; Lind M Diabetes Care; 2020 Sep; 43(9):2017-2024. PubMed ID: 32641374 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community. Chan CL; Taki I; Dong F; Hoffman M; Norris JM; Klingensmith G; Rewers MJ; Steck AK Diabetes Technol Ther; 2015 Sep; 17(9):649-56. PubMed ID: 26317880 [TBL] [Abstract][Full Text] [Related]
4. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Jin SM; Kim TH; Bae JC; Hur KY; Lee MS; Lee MK; Kim JH Diabetes Res Clin Pract; 2014 May; 104(2):266-72. PubMed ID: 24630619 [TBL] [Abstract][Full Text] [Related]
5. The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes. Maahs DM; Chase HP; Westfall E; Slover R; Huang S; Shin JJ; Kaufman FR; Pyle L; Snell-Bergeon JK Diabetes Technol Ther; 2014 May; 16(5):284-91. PubMed ID: 24450776 [TBL] [Abstract][Full Text] [Related]
6. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA; Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221 [TBL] [Abstract][Full Text] [Related]
7. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial. Lawson ML; Verbeeten KC; Courtney JM; Bradley BJ; McAssey K; Clarson C; Kirsch S; Curtis JR; Mahmud FH; Richardson C; Cooper T; Chan J; Tang K Pediatr Diabetes; 2021 Mar; 22(2):279-287. PubMed ID: 33098212 [TBL] [Abstract][Full Text] [Related]
8. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256 [TBL] [Abstract][Full Text] [Related]
9. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E; Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468 [TBL] [Abstract][Full Text] [Related]
10. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691 [TBL] [Abstract][Full Text] [Related]
11. Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data Sets. Gimenez M; Tannen AJ; Reddy M; Moscardo V; Conget I; Oliver N Diabetes Care; 2018 Feb; 41(2):326-332. PubMed ID: 29191845 [TBL] [Abstract][Full Text] [Related]
12. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA Thabit H; Prabhu JN; Mubita W; Fullwood C; Azmi S; Urwin A; Doughty I; Leelarathna L Diabetes Care; 2020 Oct; 43(10):2537-2543. PubMed ID: 32723843 [TBL] [Abstract][Full Text] [Related]
13. Glycaemia risk index uncovers distinct glycaemic variability patterns associated with remission status in type 1 diabetes. Zhong T; He B; Li X; Lei K; Tang R; Zhao B; Li X Diabetologia; 2024 Jan; 67(1):42-51. PubMed ID: 37889319 [TBL] [Abstract][Full Text] [Related]
14. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D; JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453 [TBL] [Abstract][Full Text] [Related]
15. Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. Van Dalem A; Demeester S; Balti EV; Decochez K; Weets I; Vandemeulebroucke E; Van de Velde U; Walgraeve A; Seret N; De Block C; Ruige J; Gillard P; Keymeulen B; Pipeleers DG; Gorus FK; Diabetologia; 2015 Dec; 58(12):2753-64. PubMed ID: 26409458 [TBL] [Abstract][Full Text] [Related]